Evaluate the Effect of Atorvastatin on Cerebrovascular Reactivity in Mild Cognitive Impairment (MCI)
Launched by JOHNS HOPKINS UNIVERSITY · Feb 18, 2021
Trial Information
Current as of August 19, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how a medication called atorvastatin might help improve blood flow in the brain for people with mild cognitive impairment (MCI). MCI is a condition that can affect memory and thinking skills, but it doesn't mean a person has dementia. The study is looking for participants who are aged between 21 and 34, and who have been diagnosed with MCI, specifically those who have certain challenges with memory and thinking that are worse than what is typical for their age and education. To join the study, individuals should not currently be taking atorvastatin or any other similar medications, and they should not have a history of dementia or other serious neurological conditions.
Participants in this trial can expect to undergo some tests, including brain scans, to see how well their brain's blood vessels respond. The study is currently recruiting, and those who qualify will contribute to important research that could lead to better treatments for MCI. It's a chance to be part of a project that aims to understand how medication can help with brain health. If you or someone you know is interested, it might be worthwhile to learn more about joining the study.
Gender
ALL
Eligibility criteria
- Inclusion Criteria are chosen to include participants with MCI, enriched for vascular risk factors:
- • MCI defined by Clinical Dementia Rating (CDR) of 0.5 or 1.0.
- • Memory, processing speed, executive function, language - cognitive scores \> 1.5 standard deviations below age-education norms.
- • Not demented by history.
- • Not taking statins currently or in the last 6 months.
- • Cognitive/functional impairment not likely due to another neurological disease or delirium.
- Exclusion Criteria:
- • Taking a statin currently or have taken a statin in the last 6 months.
- • Contraindications to taking a statin.
- • Transplant patient taking cyclosporine.
- • Unable to undergo MRI procedures (such as having an implanted pacemaker or defibrillator or stimulator or having non MRI compatible metal).
- • Diagnosis of dementia by history.
- • Current diagnosis of substance abuse.
- • History of stroke or myocardial infarction in past 6 months.
- • History of HIV.
About Johns Hopkins University
Johns Hopkins University, a prestigious research institution located in Baltimore, Maryland, is renowned for its commitment to advancing medical science and public health through innovative clinical trials. With a rich history of groundbreaking research and a multidisciplinary approach, the university's clinical trial initiatives focus on translating scientific discoveries into effective treatments and interventions. Leveraging state-of-the-art facilities and a collaborative network of experts, Johns Hopkins University conducts rigorous clinical studies that aim to improve patient outcomes and address critical health challenges. Its dedication to ethical standards and participant safety underscores its role as a leader in clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Baltimore, Maryland, United States
Patients applied
Trial Officials
Paul Rosenberg, MD
Principal Investigator
Johns Hopkins University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials